Drugs / V-01
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05585567 | Sep → Oct 2022 | COVID-19 | Livzon Pharmaceutical Group Inc. | Unknown | No outcome recorded |
| Phase 32 trials · 1 met primary | ||||||
| Phase 3 | NCT05096832 | Nov 2021 → Feb 2022 | COVID-19 | Livzon Pharmaceutical Group Inc. | Completed | Met primary |
| Phase 3 | NCT05096845 | Aug 2021 → Feb 2022 | COVID-19 | Livzon Pharmaceutical Group Inc. | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | V-01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05096845 ↗ |
| Known as | Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) | “Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01)” NCT05096832 ↗ |
| Modality | Vaccine | “Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01)” NCT05096832 ↗ |
| Route | Intramuscular | “Vaccination route: Intramuscular injection into the lateral deltoid of the upper arm” NCT05096832 ↗ |